Literature DB >> 9659253

Obstructive uropathy associated with myelomonocytic infiltration of the prostate.

B Hope-Gill1, J R Goepel, R C Collin.   

Abstract

A 72 year old man was diagnosed with chronic myelomonocytic leukaemia (CMML) according to the FAB group classification. He presented with symptoms of anaemia, urinary frequency, hesitancy, and nocturia. He was later admitted with acute urinary retention and acute renal failure, which resolved with treatment. A transurethral resection of the prostate was performed. Histological examination showed fibromuscular hyperplasia with dense infiltration by myelomonocytes which stained positively with chloroacetate esterase; immunohistochemical staining was positive for lysozyme, CD43, CD45, and CD68. Following treatment with oral etoposide he transformed to acute myeloid leukaemia and eventually died. Myelomonocytic infiltration of the prostate has not been reported before. This case extends the spectrum of disease previously recognised in CMML.

Entities:  

Mesh:

Year:  1998        PMID: 9659253      PMCID: PMC500685          DOI: 10.1136/jcp.51.4.340

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  Luekemic infiltration of the prostate: a case study and clinicopathological review.

Authors:  Y F Dajani; M Burke
Journal:  Cancer       Date:  1976-12       Impact factor: 6.860

2.  Lymphocytic infiltration of the prostate presenting as retention.

Authors:  G Singh; K Murray
Journal:  Urol Int       Date:  1994       Impact factor: 2.089

3.  Proposals for the classification of the myelodysplastic syndromes.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1982-06       Impact factor: 6.998

4.  Chronic myelomonocytic leukemia according to FAB classification: analysis of 35 cases.

Authors:  P Solal-Celigny; B Desaint; A Herrera; C Chastang; M Amar; M Vroclans; N Brousse; F Mancilla; M Renoux; J F Bernard
Journal:  Blood       Date:  1984-03       Impact factor: 22.113

5.  Chronic myelomonocytic leukemia: clinical features, cytogenetics, and prognosis in 30 consecutive cases.

Authors:  E P Alessandrino; E Orlandi; E Brusamolino; M Lazzarino; E Morra; C Castagnola; C Bernasconi
Journal:  Hematol Oncol       Date:  1985 Apr-Jun       Impact factor: 5.271

6.  Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival.

Authors:  A Worsley; D G Oscier; J Stevens; S Darlow; A Figes; G J Mufti; T J Hamblin
Journal:  Br J Haematol       Date:  1988-01       Impact factor: 6.998

7.  Chronic and subacute myelomonocytic leukaemia in the adult: a report of 60 cases with special reference to prognostic factors.

Authors:  P Fenaux; J P Jouet; M Zandecki; J L Lai; M Simon; J P Pollet; F Bauters
Journal:  Br J Haematol       Date:  1987-01       Impact factor: 6.998

8.  Monocytic skin infiltration in chronic myelomonocytic leukaemia.

Authors:  J A Copplestone; D G Oscier; G J Mufti; T J Hamblin
Journal:  Clin Lab Haematol       Date:  1986

9.  An autopsy study of the metastatic patterns of human leukemias.

Authors:  E Viadana; I D Bross; J W Pickren
Journal:  Oncology       Date:  1978       Impact factor: 2.935

10.  Leukaemic infiltration of the prostate.

Authors:  E Merimsky; M Baratz; Y Kahn
Journal:  Br J Urol       Date:  1981-04
  10 in total
  3 in total

1.  Renal involvement by chronic myelomonocytic leukemia requiring nephroureterectomy.

Authors:  Elias S Hyams; Raavi Gupta; Jonathan Melamed; Samir S Taneja; Ojas Shah
Journal:  Rev Urol       Date:  2009

2.  Primary Myeloid Sarcoma of the Prostate: A Case Report and Literature Review.

Authors:  Ryan Nguyen; Hamid Sayar
Journal:  Case Rep Hematol       Date:  2018-04-29

3.  Myeloid sarcoma of the periprostatic tissue and prostate: Case report and review of literature.

Authors:  Shalini Koppisetty; Brain L Edelman; Atul Rajpurkar
Journal:  Urol Ann       Date:  2016 Jul-Sep
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.